z-logo
open-access-imgOpen Access
Intense light as anticoagulant therapy in humans
Author(s) -
Yoshimasa Oyama,
Sydney Shuff,
Pavel DavizonCastillo,
Nathan Clendenen,
Tobias Eckle
Publication year - 2020
Publication title -
plos one
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.99
H-Index - 332
ISSN - 1932-6203
DOI - 10.1371/journal.pone.0244792
Subject(s) - platelet , per2 , medicine , light therapy , megakaryocyte , coagulation , platelet factor 4 , hemostasis , endocrinology , circadian rhythm , biology , microbiology and biotechnology , haematopoiesis , stem cell , circadian clock , clock
Blood coagulation is central to myocardial ischemia and reperfusion (IR) injury. Studies on the light elicited circadian rhythm protein Period 2 (PER2) using whole body Per2 -/- mice found deficient platelet function and reduced clotting which would be expected to protect from myocardial IR-injury. In contrast, intense light induction of PER2 protected from myocardial IR-injury while Per2 deficiency was detrimental. Based on these conflicting data, we sought to evaluate the role of platelet specific PER2 in coagulation and myocardial ischemia and reperfusion injury. We demonstrated that platelets from mice with tissue-specific deletion of Per2 in the megakaryocyte lineage ( Per2 loxP/loxP -PF4-CRE) significantly clot faster than platelets from control mice. We further found increases in infarct sizes or plasma troponin levels in Per2 loxP/loxP -PF4-CRE mice when compared to controls. As intense light increases PER2 protein in human tissues, we also performed translational studies and tested the effects of intense light therapy on coagulation in healthy human subjects. Our human studies revealed that intense light therapy repressed procoagulant pathways in human plasma samples and significantly reduced the clot rate. Based on these results we conclude that intense light elicited PER2 has an inhibitory function on platelet aggregation in mice. Further, we suggest intense light as a novel therapy to prevent or treat clotting in a clinical setting.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here